Pachlovid Pfizer is the first Covid-19 oral treatment to get the FDA authorization for use in the US. The health agency announced its decision today, noted that it was only available for certain patients. Although Paxlovid will not protect you from developing Covid-19, taking it quite early can prevent infection become severe.
What is Paxlovid?
Paxlovid is a pill consumed by patients, adding new options to growth – but still slim – drug warehouse developed to overcome Covid-19. Pfizer published detail about the drug in early November, revealing a decrease in hospitalization and the risk of death among patients given paxlovid immediately after positive testing.
New oral antivirus drugs are known as SARS-COV-2-3CL protease inhibitors, according to pharmaceutical companies. This drug works by blocking the enzyme needed by the virus to replicate; Inhibitors are hymld with Ritonavir, antiretroviral drugs, who work to slow down the details of the protease inhibitors.
By combining two drugs, Pfizer records, inhibitors can remain active in the patient’s body for a longer period of time – and at greater concentration – to slow down how fast the virus replicates. This, in turn, can help ensure a person’s disease does not develop into a more severe stage, even though the efficacy is based on drug-taking in the first few days of positive testing.
Patients who meet the requirements
The Paxlovid FDA authorization only includes certain patients, the agency explains today. Antivirus drugs can be given to children aged 12 and older who have a weight of at least 88lbs, as well as adults, if they have tested the positive Covid-19 and still have mild to moderate symptoms. These patients, FDA records must be considered high-risk for severe disease results to get drugs.
This drug is intended to be given in the first five days of symptoms and taken twice a day for five days. Those infected with Covid-19 can only get the drug as a prescription, with the biggest attraction is its simplicity: someone might be able to take this medicine at home immediately after testing positive, potentially avoiding hospitalization at all.
The FDA emphasized that Paxlovid was not a substitute for preventive measures, namely getting the primary series of Covid-19 vaccine and, when qualifying, booster shots. EUA is given in the midst of the rapid spread of omicrons, the latest SARS-COV-2 variants who have an interested first identified in South Africa.